A Randomized, Multicenter, Double-Blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-Negative, Cetuximab-Naive Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck After
Posted Date: Oct 11, 2017
- Investigator: Trisha Wise-Draper
- Specialties: Hematology/Oncology, Oncology, Cancer
- Type of Study: Drug
The purpose of this study is to compare the effects of the study drug, palbociclib in combination with cetuximab against placebo in combination with cetuximab. Palbociclib is not approved to treat head and neck cancer, meaning it is an investigational drug for the purpose of this study.
To Be Eligible To Participate In This Study, Participants Must Have Head And Neck Cancer That Cannot Be Treated By Surgery Or Radiation Therapy.
Pfizer A5481044, Cancer, Phase Ii, Head & Neck
For More Information:
Uc Cancer Institute